Other

Washington University

John-Stephen Taylor

Xiaoxu Li

Dipanjan Pan

Karen L Wooley

Michael John Welch

Xiankai Sun

Jeffrey L Turner

Matthew L Becker

Huafeng Fang

Raffaella Rossin

A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2'-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.

Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ('PNAs') with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

The present invention provides methods and combinations of compositions for the modulation of diseases caused by a subject possessing a disease-specific nucleic acid sequence. Included are methods for the treatment, prevention and/or inhibition of the diseases by administering a combination of a prodrug component, drug and catalytic component such that the drug is catalytically released when contacting the combination to the disease-specific nucleic acid sequence.

Nucleic acid triggered catalytic drug and probe release

Growing community of inventors

St. Louis, MO, United States of America

John-Stephen Taylor